Marina Basina

Back to Profile

Publication Details

  • Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.

    Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC, Reaven GM. Hum Reprod. 2006; 21 (1): 109-20

    Insulin sensitizers have favourable metabolic and ovarian effects in polycystic ovary syndrome (PCOS). This study examined rosiglitazone, a thiazolidinedione, in PCOS.

    PubMedID: 16155076

Stanford Medicine Resources:

Footer Links: